Introduction
Currently, drug repurposing, meaning that is to discover new applications of existing or abandoned pharmacotherapies, is an effective approach for developing novel pharmacotherapies in treating cancer (1). Many existing drugs approved by FDA, such as metformin (2), aspirin (3) and disulfiram (4), have demonstrated anticancer effects in addition to their original uses. Consequently, more approved drugs need to be found to inhibit the cancer cell growth, leading to increased choice and enhancement of the effectiveness of antitumor therapy.
Prostate cancer is one of the most common cancers worldwide, as well as a frequent cause of cancer-related death (5). Many patients with prostate cancer, having a poor prognosis, often developed resistant to the common therapies, including androgen deprivation treatment and cytotoxic drugs (6). The transcription factor STAT3 is constitutively active and has been associated with prognosis and progression in human prostate cancer (7). STAT3 is involved in oncogenesis, cell proliferation, angiogenesis, self-renewal and drug resistance. Several studies have suggested that inhibition of STAT3 signaling induces apoptosis, prevents metastasis and overcomes drug-resistance in prostate cancer (8,9). Thus, it is indicated that targeting STAT3 activation appears to be a promising treatment strategy for patients with advanced prostate cancer.
Pimozide is an FDA-approved compound used to clinically treat chronic psychosis, Tourette syndrome and resistant tics (10). Moreover, in previous studies, pimozide was shown to have anticancer effect on various carcinomas and leukemia, including melanoma (11), breast cancer (12) and myelogenous leukemia (13,14). The neuroleptic agents pimozide inhibited cell proliferation and induced apoptosis in human breast cancer cell line MCF-7 (12,15). In addition, pimozide suppressed the self-renewal capacity of chronic myelogenous leukemia cells by inhibiting STAT5 activity (13). Furthermore, our previous study showed that pimozide inhibited maintenance and tumorigenicity of hepatocellular carcinoma stem-like cells through suppressing the STAT3 activity (16). However, whether pimozide shows anticancer effect and inhibits the STAT3 activation mechanically in prostate cancer cells have not yet been fully determined.
The aim of the present study was to investigate the antitumor effects of the neuroleptic drug pimozide on prostate cancer cells. The results showed that pimozide inhibited prostate cancer cell proliferation, colony formation and sphere formation by inducing G1 phase cell cycle arrest. In addition, pimozide inhibited cell migration of prostate cancer cells in the Transwell system. Importantly, pimozide suppressed the basal STAT3 activation and rescued STAT3 activation induced by IL-6 addition in prostate cancer cells. Therefore, the antipsychotic agent pimozide may be a potential treatment strategy for patients with advanced prostate cancer.
Materials and methods
Cell lines and cell culture
Human prostate cancer cell lines DU145, LNCaP, PC3M, 22RV1 and BHP-1 (The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China) were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; Sigma, St. Louis, MO, USA). All cancer cell lines were cultured in incubator with 5% CO2 at 37°C.
Cell proliferation assay using MTT
Cell proliferation was performed by MTT colorimetric assay. Human prostate cancer cell lines DU145, LNCaP, PC3M, 22RV1 and BHP-1 were seeded into 96-well culture plates with 2,500 cells/well. Subsequently, cells were treated with pimozide at different concentration for various time intervals (24, 48 and 72 h). Next, each well was added with MTT solution and incubated for 4 h at 37°C. The supernatant fluid was removed, and DMSO solution was added. Absorbance value was finally measured using the microplate reader at 490 nm (BioTek Instruments Inc., Winooski, VT, USA).
Cell cycle assay
Cell cycle was determined by propidium iodide (PI; BD Biosciences Clontech, Palo Alto, CA, USA) staining. Briefly, equal amounts of cells were seeded in 6-well plates and treated with pimozide at different concentration for 48 h. The cells were harvested, washed with phosphate-buffered saline (PBS) containing 0.1% BSA, and then, cold absolute ethanol was added while vortexing the cells. PI buffer (40 μg/ml, containing 100 μg/ml RNase) was added, and the cells were analyzed by flow cytometry.
Colony formation assay
Cells with different concentrations of pimozide (7.5 and 15 μM) were plated in 10% FBS medium for 7 days. Cells were stained with 0.5% crystal violet in 20% ethanol and photographed. The morphology and the number of colonies were counted under stereomicroscope.
Sphere formation assay
Sphere formation assay was performed as previously described (17). To establish sphere cultures, single cells were cultured in 200 μl of serum-free DMEM/F12 medium (Gibco) supplemented with 20 ng/ml human recombinant epidermal growth factor (EGF; PeproTech, Rocky Hill, NJ, USA), 20 ng/ml human recombinant basic fibroblast growth factor (bFGF; PeproTech), and B27 (1:50; Gibco). Cells at a density of 500 cells/well were cultured in ultra-low attachment plates. Pimozide was added to the cells at the beginning. After plating for 7 days, all spheres in each well were photographed.
Transwell migration assay
Cells (1×105) in serum-free medium were seed in the upper compartment of a Transwell chamber (Corning Incorporated, Corning, NY, USA). Pimozide was added at 7.5 and 15 μM. After incubation for 48 h, the migrated cells on the lower membrane were counted after staining with 0.1% crystal violet. Results were shown as average from at least three independent experiments.
Western blot assay
Equal amounts of protein from cells sample harvested with RIPA lysis buffer were subjected to electrophoresis in SDS-polyacrylamide gel and transferred to nitrocellulose membrane (Merck Millipore, Billerica, MA, USA). Blots were detected using primary antibodies against GAPDH (Ambion, Austin, TX, USA), p21, Nanog, E-cadherin, N-cadherin, phospho-STAT3(Tyr705) (pY-STAT3), STAT3 (Cell Signaling Technology, Beverly, MA, USA), cyclin D1, c-Myc and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Antibody binding was detected with an enhanced chemiluminescence kit (Sigma).
Statistical analysis
The data were presented as the mean ± SD and analyzed using the GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). Student's t-test was used to compare the difference between two groups. The level of significance was set at P<0.05. The statistically significant results are shown as P<0.05, P<0.01.
Results
The antipsychotic agent pimozide inhibits cell proliferation of prostate cancer cells in a dose- and time-dependent manner
Initially, we examined whether the antipsychotic agent pimozide (structure shown in Fig. 1A) has anti-proliferative effect in prostate cancer cells using MTT colorimetric assay. Human prostate cancer cells DU145, LNCaP, PC3M, 22RV1 and BHP-1 were exposed to a series of concentrations (0, 5, 10, 15 and 20 μΜ) of pimozide for 24, 48 and 72 h. As shown in Fig. 1B–F, pimozide inhibited the proliferation of these five cell types dose- and time-dependently. The IC50 values at 24, 48 and 72 h were 12.62±2.60, 10.74±1.21 and 6.541±0.85 μΜ for DU145, 14.10±2.05, 11.90±3.05 and 7.21±0.70 μΜ for LNCaP, 12.07±2.54, 8.90±1.18 and 9.19±1.21 μΜ for PC3M, 10.36±2.60, 7.56±0.90 and 7.78±0.60 μΜ for BPH-1, 38.12±18.68, 18.24±4.80 and 11.12±1.84 μΜ for 22RV1 cells, respectively. The data implied that the neuroleptic drug pimozide might hold a potential therapeutic index in treating prostate cancer.
Pimozide induces G0/G1 phase cell cycle arrest of prostate cancer cells
Next, the cellular morphological observation using light microscopy showed that after pimozide treatment for 24 h the prostate cancer cells DU145 and LNCaP displayed cytoplasmic shrinkage and the number of cells was reduced (Fig. 2A). In addition, to determine whether pimozide could induce cell cycle arrest to inhibit cell growth, we analyzed the effect of pimozide on the cell cycle distribution using PI staining. After DU145 and LNCaP cells were treated with 15 μΜ pimozide for 24 h, the population of cells in the G0/G1 phase was increased significantly (P<0.01) whereas in the S phase it was decreased significantly (P<0.01) (Fig. 2B). After treatment with pimozide, DU145 cells showed a significant increase in the percentage of the G0/G1 phase cells, from 44.57±2.04 to 64.60±3.07%, while S phase was reduced from 37.27±1.92 to 21.98±1.38%. Further examination of relative cell cycle marker showed remarkable increase of p21 levels and decrease of cyclin D1 level (Fig. 2C), consistent with the G0/G1 arrest phenomenon observed in the flow cytometric analysis. These results indicated that pimozide decreased viability of prostate cancer cells in association with G0/G1 phase cell cycle arrest.
Pimozide inhibits the ability of colony and sphere forming in prostate cancer cells
Furthermore, we examined whether pimozide inhibited the ability of colony and sphere forming in prostate cancer cells. Colony and sphere formation assay showed that pimozide inhibited the self-renewal capacity of prostate cancer cell lines DU145 and LNCaP in a dose-dependent manner (Figs. 3 and 4). After treatment with 7.5 μΜ pimozide for a week, DU145 cells had a decrease of 77.90±1.11% of the colonies (Fig. 3A and B). Sphere formation assay showed that the inhibition rate was 94.48±0.28% and 99.39±0.03% in DU145 cells treated with pimozide at the concentration of 7.5 and 15 μM, respectively (Fig. 4). Similar results, evaluated by colony and sphere formation assay, were shown in LNCaP cells with pimozide. In addition, western blot assay showed that prostate cancer cells DU145 and LNCaP treated with pimozide for 48 h significantly downregulated the expression level of the stemness genes Nanog and c-Myc (Fig. 3C). These results indicated pimozide inhibited the ability of colony and sphere forming in prostate cancer cells.
Pimozide suppresses cell migration in prostate cancer cells
As demonstrated in Fig. 5A and B, both DU145 and LNCaP cells suppressed the capacity of cell migration after treatment with 7.5 and 15 μΜ pimozide compare to control without treatment (P<0.01, respectively). Using Transwell migration assay, the ability to migrate assessed in chambers without a matrix was also significantly reduced by 49.72±2.49% and 15.15±7.58% in the case of 7.5 and 15 μΜ pimozide treated DU145 cells, respectively. In addition, LNCaP cells treated with 15 μΜ pimozide had a decrease of 96.19±1.90% of migrated cells compare to control (P<0.01). We assessed whether pimozide inhibited cell migration through manipulating relative marker of epithelial-mesenchymal transition (EMT). Western blot assay showed that pimozide downregulated N-cadherin expression and upregulated E-cadherin expression in prostate cancer cells DU145 and LNCaP (Fig. 5C), suggesting that pimozide inhibited prostate cell migration through suppression of the EMT marker.
Pimozide suppresses the basal STAT3 activation and reverses the STAT3 activation induced by IL-6 in prostate cancer cells
It is clear that STAT3 signaling is of prime importance for promoting tumor progression and drug resistance as well as its potential as a therapeutic target in prostate cancer cells (18,19). The activation of STAT3 signaling was reported with high expression of STAT3 phosphorylation at tyrosine 705 (pY-STAT3). Western blot analysis was performed to validate the expression of pY-STAT3. The results showed that pimozide reduced the basal expression of pY-STAT3 in both DU145 and LNCaP cells (Fig. 6A). Moreover, it is well known that IL-6 can activate STAT3 signaling to exert function in prostate cancer cells presenting high expression of pY-STAT3 (Fig. 6B) (20,21). Furthermore, pimozide treatment reversed the expression level of phosphorylation STAT3 at tyrosine 705 induced by IL-6 addition in DU145 and LNCaP cells (Fig. 6B). These data further suggested that pimozide may inhibit STAT3 signaling activity to suppress cell growth in prostate cancer cells.
Discussion
Currently, serious efforts are made in drug discovery and development for clinical treatment of prostate cancer (22). In our previous study, it is reported that the neuroleptic drug pimozide had antitumor activity against hepatocellular carcinoma cells or stem-like cells through suppressing the STAT3 activity and may be a novel candidate drug for treating advanced hepatocellular carcinoma (16). Since STAT3 signaling is important to cell proliferation, angiogenesis and drug resistance in prostate cancer, we concluded that pimozide also inhibited cellular proliferation of prostate cancer cells. In the present study, our results showed that pimozide inhibited cell proliferation of prostate cancer cells with G0/G1 phase cell cycle arrest, evaluated by MTT, colony and sphere formation assay. Additionally, pimozide suppressed cell migration in prostate cancer cells. The mechanism of action of pimozide was considered to be due to inhibition of STAT3 activation. It indicated that the antipsychotic agent pimozide may be a potential and novel therapeutic for patients with advanced prostate cancer.
Pimozide is a clinical drug approved by FDA to treat neuroleptic disorders. Since pimozide had relatively low side-effect and a broad spectrum of molecular targets, pimozide has been used to treat other diseases during the past 20 years, including monosymptomatic hypochondriacal psychoses, body dysmorphic disorder, metastatic melanoma, trichotillomania, and trigeminal and postherpetic neuralgia (23). Previous studies show that pimozide is a well-known antagonist of serotonin 5HT7 receptors (Ki=0.5 nM) for treating anti-depressant effect and of dopamine receptor D2 (D2R) (Ki=0.33 nM) for treating schizophrenia (24–26). However, in the present study, it is reported that pimozide shows potential for use as a new anticancer agent for treating prostate cancer.
Numerous studies have demonstrated constitutive activation of STAT3 in a wide variety of human malignancies, including head and neck, breast, lung, gastric, hepatocellular, colorectal and prostate cancers (27–29). Aberrantly STAT3 activation contributes to oncogenesis by preventing apoptosis, inducing cell proliferation, angiogenesis, invasion, and metastasis as well as suppressing antitumor immune responses (30,31). Phosphorylated STAT3 dimerizes and translocates into the nucleus to bind to specific DNA response elements to induce the transcription of downstream genes, such as BCL-xL, MCL1 and c-Myc (32). Targeting STAT3 signaling results in suppression of the proliferation of various cancer cells in vitro and tumorigenicity in vivo (33,34). Therefore, the identification and development of novel drugs targeting deregulated STAT3 activation effectively remains an important scientific and clinical challenge (35,36). As yet, no direct STAT3 inhibitor has been approved for clinical use (18,36). A previous study showed that pimozide suppressed the self-renewal capacity of chronic myelogenous leukemia cells by inhibiting the cellular transcription factor STAT5 activity (15). Surprisingly, our data showed that pimozide can inhibit STAT3 activation in prostate cancer, presenting that pimozide reduced the basal expression of pY-STAT3 in both DU145 and LNCaP cells and reversed the expression level of phosphorylation STAT3 at tyrosine 705 induced by IL-6 addition. Similar results, reported by our previous work, were shown in hepatocellular carcinoma cells (16). Furthermore, another study showed that pimozide reduced STAT3 tyrosine phosphorylation in multiple myeloma cells (37). These further suggest that pimozide may be a novel and potential STAT3 inhibitor for anticancer treatment.
Although pimozide can induce cardiac toxicity, it has still not been reported to have adverse effects on other normal functional cells, such as hepatic or haematopoietic cells. A previous study showed that pimozide has almost no effect on haematopoietic progenitors derived from healthy donors (14). In addition, pimozide treatment was well tolerated with no significant effects on body weight in vivo (14). The lethal dose of pimozide is unknown for human. The LD50 is 228 mg/kg in mice and 5120 mg/kg in rats. In our previous study, we adopted 25 mg/kg dose pimozide for in vivo treatment of hepatocellular carcinoma cells by oral gavage (PO), showing no significant effects on body weight (16). The dose of pimozide in the present study is relatively lower compared to the commonly used dose for treating clinical disease. Therefore, pimozide possibly is a safe drug for treating cancer. Besides in clinical application for many years, pimozide has the significance of a translational medicine in the clinical treatment of cancer.
In conclusion, the present study is to demonstrate whether the neuroleptic drug pimozide has antitumour activity against prostate cancer cells. Here, our results showed that pimozide inhibited cell proliferation of prostate cancer cells with G0/G1 phase cell cycle arrest, as well as suppressed cells migration. Moreover, pimozide can inhibit STAT3 activation in prostate cancer. Thus, an antipsychotic agent pimozide may be a potential and novel therapeutic for patients with advanced prostate cancer.